The Janus kinase (JAK) inhibitor CTP-543 showed promising results in patients with moderate-to-severe alopecia areata (AA) according to interim results from a phase 2a study .
CTP-543 inhibits both JAK1 and JAK and is a modified version of the JAK inhibitor ruxolitinib, currently approved for the treatment of myelofibrosis and polycythaemia. In total, 104 adults with AA having at least a ≥50% hair loss were randomised to receive 4 or 8 mg CTP-543 twice daily or placebo for 24 weeks. Primary efficacy endpoint was a 50% relative reduction in Severity of Alopecia Tool (SALT) score from baseline to 24 weeks. Significantly more patients in the 8 mg group reached this endpoint compared with placebo (47.0% vs 8.6%; P<0.001). “Curves split after 16 weeks with the 8 mg dose, but we still see a steep increase of response until week 24,” explained James Cassella (Concert Pharmaceuticals, USA). An analysis according to subtype of AA showed a similar overall scal...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Oral antibiotics for acne treatment Next Article
Bermekimab – a future treatment for atopic dermatitis? »